Cargando…
Assessing the impact of COVID-19 on psychiatric clinical trials
OBJECTIVE: COVID-19 and associated measures to control the spread of the COVID-19 has significantly impacted clinical research. This study aimed to determine the impact COVID-19 has had on psychiatric clinical trials and to assess whether certain trial areas or trial types were differentially affect...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760184/ https://www.ncbi.nlm.nih.gov/pubmed/35123324 http://dx.doi.org/10.1016/j.jpsychires.2022.01.017 |
_version_ | 1784633261579829248 |
---|---|
author | Cannon, Julie A. Strathman, Annabella R. Warner, Seth Flignor, Jacob Beck, Nataly S. |
author_facet | Cannon, Julie A. Strathman, Annabella R. Warner, Seth Flignor, Jacob Beck, Nataly S. |
author_sort | Cannon, Julie A. |
collection | PubMed |
description | OBJECTIVE: COVID-19 and associated measures to control the spread of the COVID-19 has significantly impacted clinical research. This study aimed to determine the impact COVID-19 has had on psychiatric clinical trials and to assess whether certain trial areas or trial types were differentially affected. METHODS: We used information from ClinicalTrials.gov, the largest online database of clinical trial information, to examine changes in psychiatric clinical trials from January 2010–December 2020. RESULTS: Clinical trial initiation decreased in 2020, with a year-on-year percent change in trial initiation of −5.4% versus an expected percent change based on forecasting observed trends from 2010 to 2019 of 8.6%. When broken down by disease area, the distribution of trials observed in 2020 was significantly different from the predicted distribution (p < 0.00001). The greatest decrease in trial initiation was seen in Schizophrenia-specific trials, with an observed percent change of −29.2% versus an expected percent change of 3.2%. Conversely, anxiety trials saw a significant increase in trial initiation during 2020, with an observed percent change of 24.6% versus an expected percent change of 16.0%. When assessing interventional versus observational studies, data showed a significant increase in initiation of observational psychiatric clinical trials (p < 0.05), and a significant decrease in initiation of interventional psychiatric clinical trials (p < 0.01). When data was analyzed on a month-by-month time scale, 7/12 months in 2020 showed significant decreases when compared to initiation during matching months over prior years, and a single month, June, showed a significant increase. CONCLUSION: COVID-19 has had significant impacts on the initiation of psychiatric clinical trials over 2020, and this decrease in trial initiation may have long-term impacts on the development and assessment of psychiatric treatments and therapeutics. |
format | Online Article Text |
id | pubmed-8760184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87601842022-01-18 Assessing the impact of COVID-19 on psychiatric clinical trials Cannon, Julie A. Strathman, Annabella R. Warner, Seth Flignor, Jacob Beck, Nataly S. J Psychiatr Res Article OBJECTIVE: COVID-19 and associated measures to control the spread of the COVID-19 has significantly impacted clinical research. This study aimed to determine the impact COVID-19 has had on psychiatric clinical trials and to assess whether certain trial areas or trial types were differentially affected. METHODS: We used information from ClinicalTrials.gov, the largest online database of clinical trial information, to examine changes in psychiatric clinical trials from January 2010–December 2020. RESULTS: Clinical trial initiation decreased in 2020, with a year-on-year percent change in trial initiation of −5.4% versus an expected percent change based on forecasting observed trends from 2010 to 2019 of 8.6%. When broken down by disease area, the distribution of trials observed in 2020 was significantly different from the predicted distribution (p < 0.00001). The greatest decrease in trial initiation was seen in Schizophrenia-specific trials, with an observed percent change of −29.2% versus an expected percent change of 3.2%. Conversely, anxiety trials saw a significant increase in trial initiation during 2020, with an observed percent change of 24.6% versus an expected percent change of 16.0%. When assessing interventional versus observational studies, data showed a significant increase in initiation of observational psychiatric clinical trials (p < 0.05), and a significant decrease in initiation of interventional psychiatric clinical trials (p < 0.01). When data was analyzed on a month-by-month time scale, 7/12 months in 2020 showed significant decreases when compared to initiation during matching months over prior years, and a single month, June, showed a significant increase. CONCLUSION: COVID-19 has had significant impacts on the initiation of psychiatric clinical trials over 2020, and this decrease in trial initiation may have long-term impacts on the development and assessment of psychiatric treatments and therapeutics. Published by Elsevier Ltd. 2022-04 2022-01-15 /pmc/articles/PMC8760184/ /pubmed/35123324 http://dx.doi.org/10.1016/j.jpsychires.2022.01.017 Text en © 2022 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Cannon, Julie A. Strathman, Annabella R. Warner, Seth Flignor, Jacob Beck, Nataly S. Assessing the impact of COVID-19 on psychiatric clinical trials |
title | Assessing the impact of COVID-19 on psychiatric clinical trials |
title_full | Assessing the impact of COVID-19 on psychiatric clinical trials |
title_fullStr | Assessing the impact of COVID-19 on psychiatric clinical trials |
title_full_unstemmed | Assessing the impact of COVID-19 on psychiatric clinical trials |
title_short | Assessing the impact of COVID-19 on psychiatric clinical trials |
title_sort | assessing the impact of covid-19 on psychiatric clinical trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760184/ https://www.ncbi.nlm.nih.gov/pubmed/35123324 http://dx.doi.org/10.1016/j.jpsychires.2022.01.017 |
work_keys_str_mv | AT cannonjuliea assessingtheimpactofcovid19onpsychiatricclinicaltrials AT strathmanannabellar assessingtheimpactofcovid19onpsychiatricclinicaltrials AT warnerseth assessingtheimpactofcovid19onpsychiatricclinicaltrials AT flignorjacob assessingtheimpactofcovid19onpsychiatricclinicaltrials AT becknatalys assessingtheimpactofcovid19onpsychiatricclinicaltrials |